Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


Personalized estimates of breast cancer risk in clinical practice and public health.

Gail MH.

Stat Med. 2011 May 10;30(10):1090-104. doi: 10.1002/sim.4187. Epub 2011 Feb 21.


Projecting individualized absolute invasive breast cancer risk in African American women.

Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, Norman SA, Simon MS, Spirtas R, Ursin G, Bernstein L.

J Natl Cancer Inst. 2007 Dec 5;99(23):1782-92. Epub 2007 Nov 27. Erratum in: J Natl Cancer Inst. 2008 Aug 6;100(15):1118. J Natl Cancer Inst. 2008 Mar 5;100(5):373.


Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention.

Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA.

J Natl Cancer Inst. 2001 Mar 7;93(5):358-66.


Risk factor modification and projections of absolute breast cancer risk.

Petracci E, Decarli A, Schairer C, Pfeiffer RM, Pee D, Masala G, Palli D, Gail MH.

J Natl Cancer Inst. 2011 Jul 6;103(13):1037-48. doi: 10.1093/jnci/djr172. Epub 2011 Jun 24.


On criteria for evaluating models of absolute risk.

Gail MH, Pfeiffer RM.

Biostatistics. 2005 Apr;6(2):227-39.


Assessing women at high risk of breast cancer: a review of risk assessment models.

Amir E, Freedman OC, Seruga B, Evans DG.

J Natl Cancer Inst. 2010 May 19;102(10):680-91. doi: 10.1093/jnci/djq088. Epub 2010 Apr 28. Review.


Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.

Gail MH, Pfeiffer RM.

J Natl Cancer Inst. 2018 Feb 27. doi: 10.1093/jnci/djy013. [Epub ahead of print]


Digital Breast Tomosynthesis with Hologic 3D Mammography Selenia Dimensions System for Use in Breast Cancer Screening: A Single Technology Assessment [Internet].

Movik E, Dalsbø TK, Fagelund BC, Friberg EG, Håheim LL, Skår Å.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Sep 4.


Using multiple risk models with preventive interventions.

Gail MH.

Stat Med. 2012 Oct 15;31(23):2687-96. doi: 10.1002/sim.5443. Epub 2012 Jun 26.


Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.

Brewster AM, Christo DK, Lai H, Helzlsouer K.

Cancer. 2005 Mar 15;103(6):1147-53.


Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.

Quante AS, Whittemore AS, Shriver T, Hopper JL, Strauch K, Terry MB.

J Natl Cancer Inst. 2015 May 8;107(7). pii: djv124. doi: 10.1093/jnci/djv124. Print 2015 Jul.


Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk.

Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K.

J Natl Cancer Inst. 2009 Mar 18;101(6):384-98. doi: 10.1093/jnci/djp018. Epub 2009 Mar 10. Review.


Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model.

Gail MH.

J Natl Cancer Inst. 2009 Jul 1;101(13):959-63. doi: 10.1093/jnci/djp130. Epub 2009 Jun 17.


Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V.

J Natl Cancer Inst. 1999 Nov 3;91(21):1829-46. Review. Erratum in: J Natl Cancer Inst 2000 Feb 2;92(3):275.


Comparisons of two breast cancer risk estimates in women with a family history of breast cancer.

McTiernan A, Kuniyuki A, Yasui Y, Bowen D, Burke W, Culver JB, Anderson R, Durfy S.

Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):333-8.


Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States.

Maas P, Barrdahl M, Joshi AD, Auer PL, Gaudet MM, Milne RL, Schumacher FR, Anderson WF, Check D, Chattopadhyay S, Baglietto L, Berg CD, Chanock SJ, Cox DG, Figueroa JD, Gail MH, Graubard BI, Haiman CA, Hankinson SE, Hoover RN, Isaacs C, Kolonel LN, Le Marchand L, Lee IM, Lindström S, Overvad K, Romieu I, Sanchez MJ, Southey MC, Stram DO, Tumino R, VanderWeele TJ, Willett WC, Zhang S, Buring JE, Canzian F, Gapstur SM, Henderson BE, Hunter DJ, Giles GG, Prentice RL, Ziegler RG, Kraft P, Garcia-Closas M, Chatterjee N.

JAMA Oncol. 2016 Oct 1;2(10):1295-1302. doi: 10.1001/jamaoncol.2016.1025. Erratum in: JAMA Oncol. 2016 Oct 1;2(10 ):1374.


Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

CMAJ. 2001 Jun 12;164(12):1681-90. Review.


Breast cancer risk reduction: what do we know and where should we go?

Prout MN.

Medscape Womens Health. 2000 Sep-Oct;5(5):E4. Review.


Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women.

Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, Gail MH.

J Natl Cancer Inst. 2011 Jun 22;103(12):951-61. doi: 10.1093/jnci/djr154. Epub 2011 May 11.

Supplemental Content

Support Center